An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-1327. 3 National Cancer Institute. NCI dictionary - small cell lung cancer.

neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...